Xiao-Hua M.D Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiao-Hua M.D Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zhang
Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications - Jianhu Zheng
Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication Junying Wu
Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
1 shared publicationQingxin Han
Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication- Sheng M.M. Zhang
Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication - Tian-Xin Chen
Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 8 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1623455
Notoginsenoside R1 attenuates tendinopathy through inhibiting inflammation and matrix metalloproteinases expression
Research purpose: The purpose of this study is to demonstrate the effectiveness of Notoginsenoside R1 (NGR1) in treating tendinopathy and to reveal its potential mechanisms.Materials and methods: This study performed a preliminary network-based assessment of the potential targets that NGR1-associated in the treatment of tendinopathy, which includes PPI network analysis, GO enrichment, KEGG pathway enrichment analysis, and molecular docking. The therapeutic efficacy of NGR1 in vivo was then assessed using a collagenase-induced rat model of tendinopathy. Furthermore, the underlying mechanism was explored through LPS-induced inflammatory responses in tenocytes in vitro.Results: Network-based assessment indicated that key targets associated with NGR1 in treating tendinopathy may potentially include IL-6, TNF, and MMP9. In vivo studies revealed that NGR1 mitigates the pathological response of tendinopathy induced by collagenase, exhibiting a dose-dependent efficacy, with the 8 μM concentration yielding the most favorable outcomes. RNA sequencing analyses of tenocytes indicated that NGR1 potentially treats tendinopathy by modulating the synthesis of collagen and matrix metalloproteinases, as well as attenuating LPS-induced inflammatory responses. These findings aligned with results obtained from quantitative PCR, ELISA and Western blot analyses.Conclusion: NGR1 effectively moderates the progression of tendinopathy by modulating inflammatory reactions and matrix metabolism. This discovery offers a promising approach for clinical management of tendinopathy.
- 8 July 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1623455
Open AccessNotoginsenoside R1 attenuates tendinopathy through inhibiting inflammation and matrix metalloproteinases expression
Research purpose: The purpose of this study is to demonstrate the effectiveness of Notoginsenoside R1 (NGR1) in treating tendinopathy and to reveal its potential mechanisms.Materials and methods: This study performed a preliminary network-based assessment of the potential targets that NGR1-associated in the treatment of tendinopathy, which includes PPI network analysis, GO enrichment, KEGG pathway enrichment analysis, and molecular docking. The therapeutic efficacy of NGR1 in vivo was then assessed using a collagenase-induced rat model of tendinopathy. Furthermore, the underlying mechanism was explored through LPS-induced inflammatory responses in tenocytes in vitro.Results: Network-based assessment indicated that key targets associated with NGR1 in treating tendinopathy may potentially include IL-6, TNF, and MMP9. In vivo studies revealed that NGR1 mitigates the pathological response of tendinopathy induced by collagenase, exhibiting a dose-dependent efficacy, with the 8 μM concentration yielding the most favorable outcomes. RNA sequencing analyses of tenocytes indicated that NGR1 potentially treats tendinopathy by modulating the synthesis of collagen and matrix metalloproteinases, as well as attenuating LPS-induced inflammatory responses. These findings aligned with results obtained from quantitative PCR, ELISA and Western blot analyses.Conclusion: NGR1 effectively moderates the progression of tendinopathy by modulating inflammatory reactions and matrix metabolism. This discovery offers a promising approach for clinical management of tendinopathy.
- Open Access
- 27 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (10) , 7270-7284
Efficacy and safety of bicompartmental versus total knee arthroplasty for treating medial tibiofemoral compartment combined with patellofemoral compartment osteoarthritis: a systematic review and META-analysis
Background: Both bicompartmental knee arthroplasty (BKA) and total knee arthroplasty (TKA) are viable treatment options for patients with osteoarthritis affecting the medial tibiofemoral and patellofemoral compartments. The efficacy and safety of both surgical procedures were assessed through a systematic review and meta-analysis. Methods: This review was registered in the PROSPERO database and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, as well as the Cochrane Handbook for Systematic Reviews of Interventions. A comprehensive systematic literature search was conducted across the PubMed, Embase, Web of Science, and Cochrane Library databases, with a cut-off date of April 1, 2025, to identify relevant studies. We included randomized controlled trials (RCTs) and cohort studies comparing BKA with TKA for treating patients with osteoarthritis in the medial tibiofemoral and patellofemoral compartments. Studies from all countries and in any language were considered. Eligible studies were assessed for quality, data extracted, and meta-analyzed using Review Manager 5.4 software. Results: Based on strict inclusion and exclusion criteria, 14 studies, including 4 RCTs and 10 cohort studies involving 671 patients, were included in this analysis. The Knee Society (KSS) total score (mean difference [MD] = 2.57; 95% confidence interval [CI]: 0.55, 4.60; P = 0.01) and the University of California at Los Angeles score (MD = 0.56; 95% CI: 0.23, 0.89; P = 0.0009) were significantly better in the BKA group than in the TKA group; no significant differences in KSS function score were observed between the two groups at 6 and 12 months (6 months: MD = −0.61; 95% CI: −5.35, 4.13; P = 0.80; 12 months: MD = 4.72; 95% CI: −1.50, 10.94; P = 0.14), but the BKA group had higher score than the TKA group at more than 24 months (MD = 4.04; 95% CI: −0.26, 8.34; P = 0.07). Patients in the BKA group demonstrated greater joint mobility than those in the TKA group at 6 months, 12–24 months, and more than 24 months (6 months: MD = 8.00; 95% CI: 4.68, 11.31; P < 0.00001; 12–24 months: MD = 13.92; 95% CI: 9.80, 18.04; P < 0.00001; >24 months: MD = 4.63; 95% CI: 1.34, 7.91; P = 0.006). The Western Ontario and McMaster Universities Osteoarthritis Index physical function score (MD = 7.30; 95% CI: 4.34, 10.26; P < 0.00001) was higher than the TKA group in the early period. The hip–knee–ankle angle was greater in the TKA group than in the BKA group (MD = −2.94; 95% CI: −3.50, −2.32; P < 0.00001). Additionally, surgical blood loss (MD = −1.23; 95% CI: −1.58, −0.88; P < 0.00001) and hospital stay were lower in the BKA group than in the TKA group ( P < 0.05). No significant differences were found between the two groups in KSS joint score at three-time points (6 months: MD = 2.32; 95% CI: −2.31, 6.94; P = 0.33; 12 months: MD = −3.85; 95% CI: −8.79, 1.08; P = 0.13; >24 months: MD = 0.28; 95% CI: −3.26, 4.23; P = 0.80), Oxford Knee score (MD = 1.56; 95% CI: -2.40, 5.51; P = 0.44), the Short-Form-36 Health Survey (Mental Component Summary: MD = 0.10; 95% CI: −3.05, 3.25; P = 0.95; MD = −1.40; 95% CI: −3.84, 1.04; P = 0.26), timed up and go (MD = −0.28; 95% CI: −0.65, 0.10; P = 0.15), revision rate (MD = 1.92; 95% CI: 0.74, 4.98; P = 0.18), or postoperative complications (MD = 2.03; 95% CI: 0.45, 9.17; P = 0.36). Conclusion: Our results suggest that BKA may be an alternative surgical option for patients with medial-patellofemoral osteoarthritis compared to TKA, but further studies are needed to confirm this conclusion and evaluate long-term outcomes and cost-effectiveness.
- 27 June 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (10) , 7270-7284
Open AccessEfficacy and safety of bicompartmental versus total knee arthroplasty for treating medial tibiofemoral compartment combined with patellofemoral compartment osteoarthritis: a systematic review and META-analysis
Background: Both bicompartmental knee arthroplasty (BKA) and total knee arthroplasty (TKA) are viable treatment options for patients with osteoarthritis affecting the medial tibiofemoral and patellofemoral compartments. The efficacy and safety of both surgical procedures were assessed through a systematic review and meta-analysis. Methods: This review was registered in the PROSPERO database and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, as well as the Cochrane Handbook for Systematic Reviews of Interventions. A comprehensive systematic literature search was conducted across the PubMed, Embase, Web of Science, and Cochrane Library databases, with a cut-off date of April 1, 2025, to identify relevant studies. We included randomized controlled trials (RCTs) and cohort studies comparing BKA with TKA for treating patients with osteoarthritis in the medial tibiofemoral and patellofemoral compartments. Studies from all countries and in any language were considered. Eligible studies were assessed for quality, data extracted, and meta-analyzed using Review Manager 5.4 software. Results: Based on strict inclusion and exclusion criteria, 14 studies, including 4 RCTs and 10 cohort studies involving 671 patients, were included in this analysis. The Knee Society (KSS) total score (mean difference [MD] = 2.57; 95% confidence interval [CI]: 0.55, 4.60; P = 0.01) and the University of California at Los Angeles score (MD = 0.56; 95% CI: 0.23, 0.89; P = 0.0009) were significantly better in the BKA group than in the TKA group; no significant differences in KSS function score were observed between the two groups at 6 and 12 months (6 months: MD = −0.61; 95% CI: −5.35, 4.13; P = 0.80; 12 months: MD = 4.72; 95% CI: −1.50, 10.94; P = 0.14), but the BKA group had higher score than the TKA group at more than 24 months (MD = 4.04; 95% CI: −0.26, 8.34; P = 0.07). Patients in the BKA group demonstrated greater joint mobility than those in the TKA group at 6 months, 12–24 months, and more than 24 months (6 months: MD = 8.00; 95% CI: 4.68, 11.31; P < 0.00001; 12–24 months: MD = 13.92; 95% CI: 9.80, 18.04; P < 0.00001; >24 months: MD = 4.63; 95% CI: 1.34, 7.91; P = 0.006). The Western Ontario and McMaster Universities Osteoarthritis Index physical function score (MD = 7.30; 95% CI: 4.34, 10.26; P < 0.00001) was higher than the TKA group in the early period. The hip–knee–ankle angle was greater in the TKA group than in the BKA group (MD = −2.94; 95% CI: −3.50, −2.32; P < 0.00001). Additionally, surgical blood loss (MD = −1.23; 95% CI: −1.58, −0.88; P < 0.00001) and hospital stay were lower in the BKA group than in the TKA group ( P < 0.05). No significant differences were found between the two groups in KSS joint score at three-time points (6 months: MD = 2.32; 95% CI: −2.31, 6.94; P = 0.33; 12 months: MD = −3.85; 95% CI: −8.79, 1.08; P = 0.13; >24 months: MD = 0.28; 95% CI: −3.26, 4.23; P = 0.80), Oxford Knee score (MD = 1.56; 95% CI: -2.40, 5.51; P = 0.44), the Short-Form-36 Health Survey (Mental Component Summary: MD = 0.10; 95% CI: −3.05, 3.25; P = 0.95; MD = −1.40; 95% CI: −3.84, 1.04; P = 0.26), timed up and go (MD = −0.28; 95% CI: −0.65, 0.10; P = 0.15), revision rate (MD = 1.92; 95% CI: 0.74, 4.98; P = 0.18), or postoperative complications (MD = 2.03; 95% CI: 0.45, 9.17; P = 0.36). Conclusion: Our results suggest that BKA may be an alternative surgical option for patients with medial-patellofemoral osteoarthritis compared to TKA, but further studies are needed to confirm this conclusion and evaluate long-term outcomes and cost-effectiveness.